Search
Search
About
Log in
Join
Experiences with
Ipilimumab
Posts
Communities
61 public posts
Filter results
Hope to be helpful
Entered a trial treatment which has since been approved,
Ipilimumab
. For a few years after I continued my foolish behavior like nothing happened. 2018, my melanoma had evolved to stage 4 metastatic and we had no idea.
Entered a trial treatment which has since been approved,
Ipilimumab
. For a few years after I continued my foolish behavior like nothing happened. 2018, my melanoma had evolved to stage 4 metastatic and we had no idea.
Ryan2
in
Young Adults with Melanoma
4 years ago
Treatment after chemo - PARP inhibitor or immunotherapy trial?
But, there is an immunotherapy trial, nivolumab and
ipilimumab
, at MD Anderson that my MO suggests I try. She also indicated we might try the PARP inhibitor with the immunotherapy. At some point, I assume I will try Lu-177 and Ac-225.
But, there is an immunotherapy trial, nivolumab and
ipilimumab
, at MD Anderson that my MO suggests I try. She also indicated we might try the PARP inhibitor with the immunotherapy. At some point, I assume I will try Lu-177 and Ac-225.
WhiteStrat
in
Advanced Prostate Cancer
4 years ago
Synergy between radiation of metastases and immunotherapy confirmed
In one longterm trial, SBRT to bone metastases was combined with Yervoy (
ipilimumab
or "ipi"). Castration-resistant patients (who'd already had docetaxel) survived longer with the combination than with ipi alone (ipi has no effect on its own).
In one longterm trial, SBRT to bone metastases was combined with Yervoy (
ipilimumab
or "ipi"). Castration-resistant patients (who'd already had docetaxel) survived longer with the combination than with ipi alone (ipi has no effect on its own).
Tall_Allen
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Approves nivolumab Plus ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
Here is the link for full press release: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-
ipilimumab
-and-chemotherapy-first-line-treatment-metastatic-nsclc
Here is the link for full press release: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-
ipilimumab
-and-chemotherapy-first-line-treatment-metastatic-nsclc
Miranda_GO2
Administrator
in
Lung Cancer Support
4 years ago
ASCO reporting: IPI with NIVO combo has better outcome than NIVO alone
https://www.oncnet.com/news/nivolumab-plus-
ipilimumab
-extends-tfs-over-nivolumab-alone-advanced-melanoma Report out on about 1000 patients comparing IPI/NIVO combo vs NIVO alone for metastatic melanoma. TFS = treatment free survival. Peace, and be safe, Missy
https://www.oncnet.com/news/nivolumab-plus-
ipilimumab
-extends-tfs-over-nivolumab-alone-advanced-melanoma Report out on about 1000 patients comparing IPI/NIVO combo vs NIVO alone for metastatic melanoma. TFS = treatment free survival. Peace, and be safe, Missy
missyrand
Ambassador
in
Melanoma Caregivers
4 years ago
Opdivo and Yervoy combination approved for Non-small cell lung cancer
The approval of Opdivo (nivolumab) and Yervoy (
ipilimumab
) marks the first approval of combined immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable change a new avenue for treatment and more options than they have ever had.
The approval of Opdivo (nivolumab) and Yervoy (
ipilimumab
) marks the first approval of combined immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable change a new avenue for treatment and more options than they have ever had.
Miranda_GO2
Administrator
in
Lung Cancer Support
4 years ago
Latest results from MDA immunotherapy. trial for mCRPC using ipilimumab. MedPageToday & Science Translational Medicine - April 2020
Latest results from MDA immunotherapy trial for mCRPC using
ipilimumab
. Another clinical study helping to define PCa patient profiles for immunotherapy treatment.
Latest results from MDA immunotherapy trial for mCRPC using
ipilimumab
. Another clinical study helping to define PCa patient profiles for immunotherapy treatment.
cujoe
in
Fight Prostate Cancer
4 years ago
BRAF-Mutated Metastatic Melanoma: Recent Research ContextStill a question about the best frontline therapy
Second, the CR rates with nivolumab plus
ipilimumab
are much higher than with anti-PD1 alone or BRAF/MEK inhibitors (22% vs 19% versus 16%, respectively).
Second, the CR rates with nivolumab plus
ipilimumab
are much higher than with anti-PD1 alone or BRAF/MEK inhibitors (22% vs 19% versus 16%, respectively).
missyrand
Ambassador
in
Melanoma Caregivers
4 years ago
Antitumor Activity Seen With Keytruda in mCRPC
Other studies involving PD-1 inhibitor-based combination regimens have shown activity in mCRPC, including the CheckMate 650 trial of nivolumab (Opdivo) plus the CTLA-4 checkpoint inhibitor
ipilimumab
(Yervoy) and KEYNOTE-365, which showed promising antitumor activity and well-tolerated TRAEs when pembrolizumab
Other studies involving PD-1 inhibitor-based combination regimens have shown activity in mCRPC, including the CheckMate 650 trial of nivolumab (Opdivo) plus the CTLA-4 checkpoint inhibitor
ipilimumab
(Yervoy) and KEYNOTE-365, which showed promising antitumor activity and well-tolerated TRAEs when pembrolizumab
snoraste
in
Advanced Prostate Cancer
4 years ago
Screw Checkmate 650 - the “trials” of trials!
He’s getting both drugs-
Ipilimumab
and Nivolumab. The schedule is 4 treatments three weeks apart, and then
Ipilimumab
every 4 weeks for up to two years. One treatment in and two days later was in the hospital for colitis. Discharged after a day.
He’s getting both drugs-
Ipilimumab
and Nivolumab. The schedule is 4 treatments three weeks apart, and then
Ipilimumab
every 4 weeks for up to two years. One treatment in and two days later was in the hospital for colitis. Discharged after a day.
joekaty
in
Advanced Prostate Cancer
4 years ago
People of HealthUnlocked | Meet Ryan
My oncologist suggested that I go into a trial for
ipilimumab
. I could get a high dose, a low dose, or interferon randomly. I got chosen for what later turned out to be the FDA approved dose of what is now commercially called Yervoy. I finished each dose with no side effects.
My oncologist suggested that I go into a trial for
ipilimumab
. I could get a high dose, a low dose, or interferon randomly. I got chosen for what later turned out to be the FDA approved dose of what is now commercially called Yervoy. I finished each dose with no side effects.
MarketingHU
in
HealthUnlocked Blog
4 years ago
mesothelioma - anyone tried Opdivo or Yervoy?
I read about Opdivo/ Yervoy immune therapy (I believe nivolumab and
ipilimumab
are the exact drug names), could anyone share his experience? Do you think giving him intravenous injections of glucose, vitamins, protein solutions could improve his general condition?
I read about Opdivo/ Yervoy immune therapy (I believe nivolumab and
ipilimumab
are the exact drug names), could anyone share his experience? Do you think giving him intravenous injections of glucose, vitamins, protein solutions could improve his general condition?
zazi717
in
Lung Conditions Community Forum
5 years ago
Update and thank you!
BUT, with an emergency steroid pack to counteract the effects of his trial meds (
Ipilimumab
and nivolumab) he made a truly remarkable recovery- has gained back almost all of the weight lost, pain manageable, and out of bed most days. At the same time, PSA continues to shoot up.
BUT, with an emergency steroid pack to counteract the effects of his trial meds (
Ipilimumab
and nivolumab) he made a truly remarkable recovery- has gained back almost all of the weight lost, pain manageable, and out of bed most days. At the same time, PSA continues to shoot up.
joekaty
in
Advanced Prostate Cancer
4 years ago
Rash On the Chest with Muscle Weakness
Dermatomyositis may be induced by medications, including hydroxyurea, penicillamine, interferon beta, and
ipilimumab
. Acute onset / flares of dermatomyositis have been reported in association with ingestion of IsaLean, an herbal supplement.
Dermatomyositis may be induced by medications, including hydroxyurea, penicillamine, interferon beta, and
ipilimumab
. Acute onset / flares of dermatomyositis have been reported in association with ingestion of IsaLean, an herbal supplement.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
5 years ago
Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic CRPC.
ASCO GU 2019: Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus
Ipilimumab
for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Low response rates (10% to 25%) and significant side effects (grade 3-5 adverse events in around 50% of the patients).
ASCO GU 2019: Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus
Ipilimumab
for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Low response rates (10% to 25%) and significant side effects (grade 3-5 adverse events in around 50% of the patients).
tango65
in
Advanced Prostate Cancer
5 years ago
What is the Current Status of Yervoy (Ipilimumab)?
What is the Current Status of Yervoy (
Ipilimumab
)? When does it become available? What does it's effectiveness on prostate cancer look like?
What is the Current Status of Yervoy (
Ipilimumab
)? When does it become available? What does it's effectiveness on prostate cancer look like?
cesanon
in
Advanced Prostate Cancer
5 years ago
Scan results
Once he is down to that, his oncologist is going to try and challenge his system again with BOTH the
ipilimumab
and the nivolumab. He has 2 more cycles of that, and if he can get through that would be amazing.
Once he is down to that, his oncologist is going to try and challenge his system again with BOTH the
ipilimumab
and the nivolumab. He has 2 more cycles of that, and if he can get through that would be amazing.
kellyOd
in
Melanoma Caregivers
5 years ago
Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care—Part 1: The Non-Androgen–Targetable Pathways in Castration-Resist
Earlier trials of the cytotoxic T-lymphocyte–associated antigen 4 inhibitor
ipilimumab
and the PD-1 inhibitor nivolumab were disappointing. The authors highlight the phase III CA184-095 trial, which illustrated no survival advantage for
ipilimumab
vs placebo in chemotherapy-naive patients.
Earlier trials of the cytotoxic T-lymphocyte–associated antigen 4 inhibitor
ipilimumab
and the PD-1 inhibitor nivolumab were disappointing. The authors highlight the phase III CA184-095 trial, which illustrated no survival advantage for
ipilimumab
vs placebo in chemotherapy-naive patients.
JLS1
in
Advanced Prostate Cancer
5 years ago
Names of targeted therapies ...mab and ...ib
I think it gives a really clear and useful explanation of names like "
ipilimumab
" and "imatinib". https://voice.ons.org/news-and-views/the-names-of-targeted-therapies-give-clues-to-how-they-work Alan
I think it gives a really clear and useful explanation of names like "
ipilimumab
" and "imatinib". https://voice.ons.org/news-and-views/the-names-of-targeted-therapies-give-clues-to-how-they-work Alan
AlanMeyer
in
Advanced Prostate Cancer
5 years ago
Starting ipi/nivo next week
I did participate in the study for
ipilimumab
many years ago before the FDA approved it with no side effects, so I hope to tolerate the infusions well. My body is healthy, and my blood work comes back recently with all panels reading like one before the taf/mek.
I did participate in the study for
ipilimumab
many years ago before the FDA approved it with no side effects, so I hope to tolerate the infusions well. My body is healthy, and my blood work comes back recently with all panels reading like one before the taf/mek.
Ryan2
in
Young Adults with Melanoma
5 years ago
1
2
3
4
Next page
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
38 results
Melanoma Caregivers
6 results
Lung Cancer Support
3 results
View top 10 communities
Sort by
Most Relevant
Newest